{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:48:33Z","timestamp":1788846513363,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00042"],"award-info":[{"award-number":["75N93019C00042"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93023C00043"],"award-info":[{"award-number":["75N93023C00043"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93024C00022"],"award-info":[{"award-number":["75N93024C00022"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.vaccine.2025.127778","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T21:09:41Z","timestamp":1759957781000},"page":"127778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Enhancing vaccine immunogenicity through heterologous prime-boost regimen with multiple nasal boosting with liposomal TLR7 ligand"],"prefix":"10.1016","volume":"65","author":[{"given":"Tomoko","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumi","family":"Sato-Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renna","family":"Cozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Mclaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Anguiano","family":"Quiroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikunj M.","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard B.","family":"Cottam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127778_bb0005","first-page":"15","article-title":"Recent advances in intranasal liposomes for drug, gene, and vaccine delivery","author":"Duong","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.vaccine.2025.127778_bb0010","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jama.282.2.137","article-title":"Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial","volume":"282","author":"Nichol","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2025.127778_bb0015","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41577-021-00583-2","article-title":"Mucosal vaccines - fortifying the frontiers","volume":"22","author":"Lavelle","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2025.127778_bb0020","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/0018578718767103","article-title":"Zoster Vaccine Recombinant","volume":"53","author":"Stoker","year":"2018","journal-title":"Adjuvanted Hosp Pharm"},{"key":"10.1016\/j.vaccine.2025.127778_bb0025","first-page":"11","article-title":"Intranasal liposomal formulation of spike protein adjuvanted with CpG protects and boosts heterologous immunity of hACE2 transgenic mice to SARS-CoV-2 infection","author":"Russo","year":"2023","journal-title":"Vaccines (Basel)."},{"key":"10.1016\/j.vaccine.2025.127778_bb0030","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.immuni.2011.05.006","article-title":"Toll-like receptors and their crosstalk with other innate receptors in infection and immunity","volume":"34","author":"Kawai","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2025.127778_bb0035","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1158\/0008-5472.CAN-12-3229","article-title":"TLRs as miRNA receptors","volume":"72","author":"Fabbri","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2025.127778_bb0040","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.immuni.2010.03.012","article-title":"Intracellular toll-like receptors","volume":"32","author":"Blasius","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2025.127778_bb0045","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1016\/j.vaccine.2016.06.080","article-title":"Evaluation of novel synthetic TLR7\/8 agonists as vaccine adjuvants","volume":"34","author":"Smith","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127778_bb0050","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1021\/bc900054q","article-title":"Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates","volume":"20","author":"Chan","year":"2009","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.vaccine.2025.127778_bb0055","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/CMR.0b013e328340ce6c","article-title":"Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2","volume":"21","author":"Hayashi","year":"2011","journal-title":"Melanoma Res"},{"key":"10.1016\/j.vaccine.2025.127778_bb0060","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000355217","article-title":"Innate immune protection against infectious diseases by pulmonary administration of a phospholipid-conjugated TLR7 ligand","volume":"6","author":"Wu","year":"2014","journal-title":"J Innate Immun"},{"key":"10.1016\/j.vaccine.2025.127778_bb0065","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1803281115","article-title":"Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist","volume":"115","author":"Hosoya","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2025.127778_bb0070","first-page":"91","article-title":"Synthetic toll-like receptor 4 (TLR4) and TLR7 ligands work additively via MyD88 to induce protective antiviral immunity in mice","author":"Goff","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127778_bb0075","first-page":"10","article-title":"A dual adjuvant system for intranasal boosting of local and systemic immunity for influenza vaccination","author":"Sato-Kaneko","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127778_bb0080","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1126\/science.3107127","article-title":"Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production","volume":"236","author":"Snapper","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2025.127778_bb0085","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.4049\/jimmunol.170.8.4102","article-title":"A subset of toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells","volume":"170","author":"Datta","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2025.127778_bb0090","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1002\/jcp.26361","article-title":"Nanoliposomes as the adjuvant delivery systems in cancer immunotherapy","volume":"233","author":"Zamani","year":"2018","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.vaccine.2025.127778_bb0095","first-page":"10","article-title":"Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems","author":"Danaei","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.vaccine.2025.127778_bb0100","first-page":"274","article-title":"A comprehensive review on novel liposomal methodologies, commercial formulations","volume":"12","author":"Andra","year":"2022","journal-title":"Clinical Trials and Patents Bionanoscience"},{"key":"10.1016\/j.vaccine.2025.127778_bb0105","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1182\/blood-2011-04-348839","article-title":"TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway","volume":"118","author":"Oh","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2025.127778_bb0110","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3389\/fimmu.2017.01075","article-title":"The toll for trafficking: toll-like receptor 7 delivery to the endosome","volume":"8","author":"Petes","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127778_bb0115","doi-asserted-by":"crossref","first-page":"ra3","DOI":"10.1126\/scisignal.aab2191","article-title":"Comprehensive RNAi-based screening of human and mouse TLR pathways identifies species-specific preferences in signaling protein use","volume":"9","author":"Sun","year":"2016","journal-title":"Sci Signal"},{"key":"10.1016\/j.vaccine.2025.127778_bb0120","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/ajh.23280","article-title":"Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies","volume":"87","author":"Weigel","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.vaccine.2025.127778_bb0125","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.1158\/1078-0432.CCR-07-1443","article-title":"First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer","volume":"13","author":"Dudek","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2025.127778_bb0130","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jconrel.2009.10.022","article-title":"Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen","volume":"142","author":"Henriksen-Lacey","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2025.127778_bb0135","first-page":"12","article-title":"Injectable lipid-based depot formulations: where do we stand?","author":"Rahnfeld","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.vaccine.2025.127778_bb0140","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.4049\/jimmunol.136.7.2348","article-title":"Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins","volume":"136","author":"Mosmann","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2025.127778_bb0145","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/361841","article-title":"A new method for the evaluation of vaccine safety based on comprehensive gene expression analysis","volume":"2010","author":"Momose","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.vaccine.2025.127778_bb0150","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1152\/ajpregu.00527.2007","article-title":"Mast cell-dependent anorexia and hypothermia induced by mucosal activation of toll-like receptor 7","volume":"295","author":"Hayashi","year":"2008","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.vaccine.2025.127778_bb0155","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1016\/j.vaccine.2009.06.098","article-title":"Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine","volume":"27","author":"Russell","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127778_bb0160","doi-asserted-by":"crossref","first-page":"931","DOI":"10.15585\/mmwr.mm7129e1","article-title":"Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2\/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021\u2013June 2022","volume":"71","author":"Link-Gelles","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.127778_bb0165","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41541-024-00912-1","article-title":"Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine","volume":"9","author":"Bissett","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.127778_bb0170","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.coi.2012.03.008","article-title":"Adjuvants for human vaccines","volume":"24","author":"Alving","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2025.127778_bb0175","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/14760584.2019.1604231","article-title":"Selection of adjuvants for vaccines targeting specific pathogens","volume":"18","author":"Sarkar","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127778_bb0180","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2019.04.025","article-title":"Liposomes used as a vaccine adjuvant-delivery system: from basics to clinical immunization","volume":"303","author":"Wang","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2025.127778_bb0185","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fcimb.2013.00013","article-title":"Vaccine delivery using nanoparticles","volume":"3","author":"Gregory","year":"2013","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2025.127778_bb0190","first-page":"3","article-title":"Barriers to liposomal gene delivery: from application site to the target","volume":"15","author":"Saffari","year":"2016","journal-title":"Iran J Pharm Res"},{"key":"10.1016\/j.vaccine.2025.127778_bb0195","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ni758","article-title":"Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway","volume":"3","author":"Hemmi","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2025.127778_bb0200","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1128\/JVI.03337-14","article-title":"Synthetic toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses","volume":"89","author":"Goff","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127778_bb0205","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fmicb.2018.00123","article-title":"Universal vaccines and vaccine platforms to protect against influenza viruses in humans and agriculture","volume":"9","author":"Raj\u00e3o","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2025.127778_bb0210","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/intimm\/dxaa029","article-title":"Impaired mucociliary motility enhances antigen-specific nasal IgA immune responses to a cholera toxin-based nasal vaccine","volume":"32","author":"Lan","year":"2020","journal-title":"Int Immunol"},{"key":"10.1016\/j.vaccine.2025.127778_bb0215","first-page":"14","article-title":"Development of nasal vaccines and the associated challenges","author":"Nian","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.vaccine.2025.127778_bb0220","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/9780470942390.mo110217","article-title":"Health evaluation of experimental laboratory mice","volume":"2","author":"Burkholder","year":"2012","journal-title":"Curr Protoc Mouse Biol"},{"key":"10.1016\/j.vaccine.2025.127778_bb0225","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3389\/fimmu.2020.01207","article-title":"A novel synthetic dual agonistic liposomal TLR4\/7 adjuvant promotes broad immune responses in an influenza vaccine with minimal reactogenicity","volume":"11","author":"Sato-Kaneko","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127778_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1216402","article-title":"Pivotal role of tissue-resident memory lymphocytes in the control of mucosal infections: can mucosal vaccination induce protective tissue-resident memory T and B cells?","volume":"14","author":"Longet","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127778_bb0235","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40545-022-00411-5","article-title":"Management of COVID-19 vaccines cold chain logistics: a scoping review","volume":"15","author":"Fahrni","year":"2022","journal-title":"J Pharm Policy Pract"},{"key":"10.1016\/j.vaccine.2025.127778_bb0240","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1016\/j.vaccine.2023.05.027","article-title":"Upscaling vaccine manufacturing capacity - key bottlenecks and lessons learned","volume":"41","author":"Feddema","year":"2023","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25010758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25010758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:04:10Z","timestamp":1780373050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25010758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":48,"alternative-id":["S0264410X25010758"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127778","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing vaccine immunogenicity through heterologous prime-boost regimen with multiple nasal boosting with liposomal TLR7 ligand","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127778","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127778"}}